Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Vaccines news

Show

From To
Combined HIV and hepatitis C virus vaccination a possibility

The research showed that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens (molecules capable of inducing an immune response).

Published
13 April 2016
From
EASL press release
HIV vaccine candidate shows promise with monkeys

Monkeys in the study did not show signs of persistent infection until they were exposed to nearly 70,000 times the average amount of virus an infected man passes to a partner during intercourse.

Published
12 April 2016
From
UPI.com
UNITAID study looks at delinking cost of R&D from price of medicines

UNITAID has published a report that asks how best to separate the costs of research and development for vaccines, medicines and diagnostics from their prices – a concept known as “delinkage”.

Published
02 March 2016
From
UNITAID
Study does not support routine HPV quadrivalent vaccination to protect against anal cancer in older people living with HIV

The quadrivalent HPV vaccine Gardasil does not protect older adults with HIV against persistent anal infection with human papillomavirus (HPV) or the development of HSIL, but the

Published
29 February 2016
By
Keith Alcorn
New tools to fight AIDS

Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.

Published
21 February 2016
From
Boston Globe
HIV-infected vaginal cells do not transmit HIV if plasma viral load is undetectable, researchers find

A group of researchers have cleared up an important question about HIV transmission, in experiments on mice. Although HIV-infected CD4 cells persist in the vagina even on

Published
15 February 2016
By
Gus Cairns
Combination nanotherapy drastically reduces the amount of HIV produced by cells in mice

A combination of fine-particle formulations of the drugs atazanavir and ritonavir, plus an immune-dampener drug designed to induce cells to keep hold of the drugs for longer,

Published
05 February 2016
By
Gus Cairns
Activists United and Ignited by Urgency for HIV Prevention in Europe: EATG and AVAC call for the rollout of PrEP as a proven HIV prevention strategy

Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.

Published
03 February 2016
From
EATG
About that latest big Gates Foundation bet for HIV prevention

It isn’t too out of the ordinary for Gates Foundation grant awards to soar into the eight- and even nine-figure range. So, its $20 million grant to Moderna Therapeutics to support its continuing development of a novel but promising HIV prevention therapy isn’t particularly extraordinary. But what is unusual...is that the total potential commitment from the foundation could reach upwards of $100 million—around 70 percent of the Gates Foundation’s HIV/AIDS grants for all of last year.

Published
27 January 2016
From
Inside Philanthropy
A European Alliance dedicated to accelerating new concepts in HIV Vaccine research

The European Commission has granted over 22 million Euros to the European HIV Vaccine Alliance (EHVA) to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. The grant is supplemented with additional 6 million Euros from the Swiss government for the Swiss project partners.

Published
27 January 2016
From
Eurekalert Inf Dis
← First12345...33Next →

Filter by country